Mariela Vera Roa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariela Vera Roa has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Pontillo
Universidade de São Paulo, Brazil
2 shared publications Raylane Gonçalves Cambui
2 shared publicationsAlessandra Pontillo
Intitute of Biomedical Science (ICB) - University of São Paulo
1 shared publicationAmanda Lara
Faculdade de Medicina
1 shared publication- Carlos Victor Montefusco-Pereira
Independent Researcher in Data Science and Artificial Intelligence in Industrial Pharmaceutics, 12103 Berlin, Germany
1 shared publication - Daniel Antunes Moreno
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 21 May 2024
- Published by Springer Nature in Research Square
NLRP1 variants affect B cells sensitivity to DPP9 inhibition
Inflammasome genetics affect several multifactorial diseases' development and severity, but the exact mechanism and cell types involved are mainly unknown. Recent findings have demonstrated the activation of caspase-1 and the release of IL-1β in B lymphocytes, leading us to hypothesize that genetic variants within the inflammasome may influence B cell functions and contribute to pathological immune responses. We previously reported the significance of NLRP3 and its variants in the dysregulation of B cells during chronic HIV infection. Here, we demonstrate that the inflammasome activation in human CD19+ cells is influenced by NLRP1 genetic variants yet associated with B cell-mediated diseases. The DPP-9 inhibitor ValBoro-Pro (VbP; Talabostat) was used to stimulate the two inflammasome sensors, NLRP1 and CARD8. First, we demonstrated that VbP induces caspase-1-dependent pyroptosis, but not IL-1β release, in CD19+ cells. Then, we evaluated the impact of common functional variants in NLRP1 and CARD8 genes on inflammasome activation in those cells. Therefore, our study identifies NLRP1 missense variants that impact B lymphocyte response to DPP9 inhibition. This implies a potential direct association between NLRP1 variants, B cell-mediated diseases, such as autoimmune and allergic conditions, and cancer.
- 21 May 2024
- Published by Springer Nature in Research Square
Open AccessNLRP1 variants affect B cells sensitivity to DPP9 inhibition
Inflammasome genetics affect several multifactorial diseases' development and severity, but the exact mechanism and cell types involved are mainly unknown. Recent findings have demonstrated the activation of caspase-1 and the release of IL-1β in B lymphocytes, leading us to hypothesize that genetic variants within the inflammasome may influence B cell functions and contribute to pathological immune responses. We previously reported the significance of NLRP3 and its variants in the dysregulation of B cells during chronic HIV infection. Here, we demonstrate that the inflammasome activation in human CD19+ cells is influenced by NLRP1 genetic variants yet associated with B cell-mediated diseases. The DPP-9 inhibitor ValBoro-Pro (VbP; Talabostat) was used to stimulate the two inflammasome sensors, NLRP1 and CARD8. First, we demonstrated that VbP induces caspase-1-dependent pyroptosis, but not IL-1β release, in CD19+ cells. Then, we evaluated the impact of common functional variants in NLRP1 and CARD8 genes on inflammasome activation in those cells. Therefore, our study identifies NLRP1 missense variants that impact B lymphocyte response to DPP9 inhibition. This implies a potential direct association between NLRP1 variants, B cell-mediated diseases, such as autoimmune and allergic conditions, and cancer.
- Open Access
- 3 January 2024
- Published by Springer Nature in Research Square
NLRP1 and NLRP3 trigger inflammasome activation in CD8+ T cells of ART-treated HIV patients and contribute differently to their chronic activation
Chronic HIV infection leads to persistent immune activation and inflammation, which can impair the function of CD8+ T cells and their immune competence against infections and tumours. Independently from anti-retroviral treatment, in HIV patients, circulating leukocytes exhibit heightened expression of exhaustion markers and inflammasome-related genes. This study delves into the dysregulation of the inflammasome in CD8+ T lymphocytes of HIV-infected individuals and explores its impact on cell functionality, contributing to persistent inflammation. Our findings demonstrate that HIV CD8+ cells present a basal moderate activation of caspase-1, further increased by DPP-8/9 inhibition and TCR stimulation through activating the NLRP1/ASC and NLRP3/ASC pathways, respectively. Due to inflammasome activation, the HIV CD8+ T cells undergo GSDMD-induced pyroptosis. Compared with healthy donors’ CD8+ T cells, we observed resistance to NLRP1/caspase-1/GSDMD pyroptosis in HIV cells, compatible with the constitutive activation state of those cells. Moreover, the activation of the inflammasome is directly correlated with IFN-Ɣ secretion and with the expression of exhaustion markers on CD8+ T cells. Genotype-guided assays confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells and revealed differential activation in HIV patients. In summary, we confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells. We addressed how they are differentially activated in HIV patients, suggesting the inflammasome as a potential novel therapeutic target for HIV-related chronic inflammation. Keywords: HIV, CD8+ lymphocytes, inflammasome, pyroptosis, NLRP3, NLRP1, CARD8.
- 3 January 2024
- Published by Springer Nature in Research Square
Open AccessNLRP1 and NLRP3 trigger inflammasome activation in CD8+ T cells of ART-treated HIV patients and contribute differently to their chronic activation
Chronic HIV infection leads to persistent immune activation and inflammation, which can impair the function of CD8+ T cells and their immune competence against infections and tumours. Independently from anti-retroviral treatment, in HIV patients, circulating leukocytes exhibit heightened expression of exhaustion markers and inflammasome-related genes. This study delves into the dysregulation of the inflammasome in CD8+ T lymphocytes of HIV-infected individuals and explores its impact on cell functionality, contributing to persistent inflammation. Our findings demonstrate that HIV CD8+ cells present a basal moderate activation of caspase-1, further increased by DPP-8/9 inhibition and TCR stimulation through activating the NLRP1/ASC and NLRP3/ASC pathways, respectively. Due to inflammasome activation, the HIV CD8+ T cells undergo GSDMD-induced pyroptosis. Compared with healthy donors’ CD8+ T cells, we observed resistance to NLRP1/caspase-1/GSDMD pyroptosis in HIV cells, compatible with the constitutive activation state of those cells. Moreover, the activation of the inflammasome is directly correlated with IFN-Ɣ secretion and with the expression of exhaustion markers on CD8+ T cells. Genotype-guided assays confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells and revealed differential activation in HIV patients. In summary, we confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells. We addressed how they are differentially activated in HIV patients, suggesting the inflammasome as a potential novel therapeutic target for HIV-related chronic inflammation. Keywords: HIV, CD8+ lymphocytes, inflammasome, pyroptosis, NLRP3, NLRP1, CARD8.
- Open Access
- 13 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10058
USP15-USP7 Axis and UBE2T Differential Expression May Predict Pathogenesis and Poor Prognosis in De Novo Myelodysplastic Neoplasm
The aim of this study was to evaluate the expression of USP7, USP15, UBE2O, and UBE2T genes in Myelodysplastic neoplasm (MDS) to identify possible targets of ubiquitination and deubiquitination in MDS pathobiology. To achieve this, eight datasets from the Gene Expression Omnibus (GEO) database were integrated, and the expression relationship of these genes was analyzed in 1092 MDS patients and healthy controls. Our results showed that UBE2O, UBE2T, and USP7 were upregulated in MDS patients compared with healthy individuals, but only in mononucleated cells collected from bone marrow samples (p < 0.001). In contrast, only the USP15 gene showed a downregulated expression compared with healthy individuals (p = 0.03). Additionally, the upregulation of UBE2T expression was identified in MDS patients with chromosomal abnormalities compared with patients with normal karyotypes (p = 0.0321), and the downregulation of UBE2T expression was associated with MDS hypoplastic patients (p = 0.033). Finally, the USP7 and USP15 genes were strongly correlated with MDS (r = 0.82; r2 = 0.67; p < 0.0001). These findings suggest that the differential expression of the USP15-USP7 axis and UBE2T may play an important role in controlling genomic instability and the chromosomal abnormalities that are a striking characteristic of MDS.
- 13 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10058
Open AccessUSP15-USP7 Axis and UBE2T Differential Expression May Predict Pathogenesis and Poor Prognosis in De Novo Myelodysplastic Neoplasm
The aim of this study was to evaluate the expression of USP7, USP15, UBE2O, and UBE2T genes in Myelodysplastic neoplasm (MDS) to identify possible targets of ubiquitination and deubiquitination in MDS pathobiology. To achieve this, eight datasets from the Gene Expression Omnibus (GEO) database were integrated, and the expression relationship of these genes was analyzed in 1092 MDS patients and healthy controls. Our results showed that UBE2O, UBE2T, and USP7 were upregulated in MDS patients compared with healthy individuals, but only in mononucleated cells collected from bone marrow samples (p < 0.001). In contrast, only the USP15 gene showed a downregulated expression compared with healthy individuals (p = 0.03). Additionally, the upregulation of UBE2T expression was identified in MDS patients with chromosomal abnormalities compared with patients with normal karyotypes (p = 0.0321), and the downregulation of UBE2T expression was associated with MDS hypoplastic patients (p = 0.033). Finally, the USP7 and USP15 genes were strongly correlated with MDS (r = 0.82; r2 = 0.67; p < 0.0001). These findings suggest that the differential expression of the USP15-USP7 axis and UBE2T may play an important role in controlling genomic instability and the chromosomal abnormalities that are a striking characteristic of MDS.
- Open Access
NLRP3 and NLRP1/CARD8 pathways differently contribute to pyroptosis of CD8+ T cells of ART-treated HIV patients
HIV-infected (HIV) patients exhibit immune dysregulation independently of antiretroviral therapy. The inflammasome, a cytosolic complex responsible for cleavage of the inflammatory cytokines IL -1β and IL -18 and pyroptosis, is highly activated in peripheral blood mononuclear cells of HIV patients, suggesting its involvement in leukocyte dysfunction. While monocytes, B cells, and CD4+ T cells have been studied, little is known about CD8+ T lymphocytes. Therefore, we proposed to characterize the inflammasome activation in these cells, both the NLRP3 and NLRP1/CARD8 pathways, which are partially described in T cells. CD8+ T lymphocytes from non-HIV healthy donors (HD) and HIV patients were analyzed ex vivo and stimulated in vitro with known activators of NLRP3 (α-CD3/α-CD28), NLRP1 and CARD8 (DPP9 inhibitor ValboroPro, VbP) to assess inflammasome activation. HIV CD8+ T cells present a constitutively activated caspase-1 which positively correlates with the cell activation state. HIV CD8+ T cells were more activated and more resistant to VbP-induced pyroptosis than HD. On the other way, HIV CD8+ T lymphocytes showed higher pyroptosis in response to α-CD3/α-CD28. These findings suggest that the NLRP3 pathway is significantly dysregulated in those patients, and TCR stimulation may result in cell loss. At the same time, being HIV CD8+ T cells constitutively activated, other inflammasome pathways, such as NLRP1 or CARD8, present a delayed activation.
Open AccessNLRP3 and NLRP1/CARD8 pathways differently contribute to pyroptosis of CD8+ T cells of ART-treated HIV patients
HIV-infected (HIV) patients exhibit immune dysregulation independently of antiretroviral therapy. The inflammasome, a cytosolic complex responsible for cleavage of the inflammatory cytokines IL -1β and IL -18 and pyroptosis, is highly activated in peripheral blood mononuclear cells of HIV patients, suggesting its involvement in leukocyte dysfunction. While monocytes, B cells, and CD4+ T cells have been studied, little is known about CD8+ T lymphocytes. Therefore, we proposed to characterize the inflammasome activation in these cells, both the NLRP3 and NLRP1/CARD8 pathways, which are partially described in T cells. CD8+ T lymphocytes from non-HIV healthy donors (HD) and HIV patients were analyzed ex vivo and stimulated in vitro with known activators of NLRP3 (α-CD3/α-CD28), NLRP1 and CARD8 (DPP9 inhibitor ValboroPro, VbP) to assess inflammasome activation. HIV CD8+ T cells present a constitutively activated caspase-1 which positively correlates with the cell activation state. HIV CD8+ T cells were more activated and more resistant to VbP-induced pyroptosis than HD. On the other way, HIV CD8+ T lymphocytes showed higher pyroptosis in response to α-CD3/α-CD28. These findings suggest that the NLRP3 pathway is significantly dysregulated in those patients, and TCR stimulation may result in cell loss. At the same time, being HIV CD8+ T cells constitutively activated, other inflammasome pathways, such as NLRP1 or CARD8, present a delayed activation.